Credit Agricole S A Increases Stock Holdings in Halozyme Therapeutics, Inc. $HALO

Key Points

• Credit Agricole S A has significantly increased its holdings in Halozyme Therapeutics by 251.4%, acquiring 38,855 shares worth approximately $2.48 million as of the latest SEC filing.
• Halozyme Therapeutics reported impressive quarterly earnings with an EPS of $1.54, surpassing analyst estimates, and the revenue grew by 40.8% year-over-year, totaling $325.72 million.
• Wall Street analysts have mixed reviews on the stock, with a consensus rating of "Hold" and an average target price of $67.11, indicating varied expectations for future performance.

Credit Agricole S A boosted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 251.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,855 shares of the biopharmaceutical company's stock after buying an additional 27,799 shares during the quarter. Credit Agricole S A's holdings in Halozyme Therapeutics were worth $2,479,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Isthmus Partners LLC grew its position in Halozyme Therapeutics by 2.5% during the 1st quarter. Isthmus Partners LLC now owns 6,875 shares of the biopharmaceutical company's stock worth $439,000 after purchasing an additional 169 shares during the last quarter. OneDigital Investment Advisors LLC lifted its stake in Halozyme Therapeutics by 1.7% during the 1st quarter. OneDigital Investment Advisors LLC now owns 10,176 shares of the biopharmaceutical company's stock valued at $649,000 after acquiring an additional 175 shares during the period. Park Place Capital Corp lifted its stake in Halozyme Therapeutics by 20.1% during the 1st quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company's stock valued at $69,000 after acquiring an additional 182 shares during the period. Xponance Inc. lifted its stake in Halozyme Therapeutics by 1.1% during the 1st quarter. Xponance Inc. now owns 18,652 shares of the biopharmaceutical company's stock valued at $1,190,000 after acquiring an additional 198 shares during the period. Finally, Bessemer Group Inc. lifted its stake in Halozyme Therapeutics by 62.9% during the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 207 shares during the period. Institutional investors own 97.79% of the company's stock.

Insider Activity

In other news, CEO Helen Torley sold 20,000 shares of the company's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $63.51, for a total transaction of $1,270,200.00. Following the completion of the sale, the chief executive officer owned 733,719 shares of the company's stock, valued at $46,598,493.69. This represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 80,000 shares of company stock worth $4,532,600 over the last ninety days. 2.40% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts have commented on the stock. The Goldman Sachs Group initiated coverage on shares of Halozyme Therapeutics in a research note on Thursday, July 10th. They set a "neutral" rating and a $55.00 price objective for the company. JMP Securities boosted their target price on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the company a "market outperform" rating in a research note on Wednesday, August 6th. Leerink Partners cut shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 target price for the company. in a research note on Tuesday, May 13th. HC Wainwright upped their price objective on shares of Halozyme Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research report on Wednesday, August 6th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a "neutral" rating in a research report on Thursday, August 7th. Four investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $67.11.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock traded down $0.23 during trading hours on Friday, reaching $72.58. 128,229 shares of the company's stock were exchanged, compared to its average volume of 1,959,050. Halozyme Therapeutics, Inc. has a 1 year low of $42.01 and a 1 year high of $74.07. The company has a market capitalization of $8.49 billion, a P/E ratio of 16.63, a price-to-earnings-growth ratio of 0.42 and a beta of 1.17. The business has a fifty day moving average of $60.28 and a two-hundred day moving average of $59.16. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The business had revenue of $325.72 million during the quarter, compared to analyst estimates of $282.66 million. During the same quarter in the prior year, the firm earned $0.91 earnings per share. The company's revenue for the quarter was up 40.8% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. As a group, research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.